Example Validation Master Plan | IVT - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Example Validation Master Plan | IVT

IVT

Validation Week
SPOTLIGHT EVENT

IVT’s 19th Annual
Validation Week

October 22-24, 2013
San Diego, California

Brochure | Register

RELATED ARTICLES

More in GMPs/Validation

Tim Fields
Example of process validation life cycle

This Validation Master Plan serves as a summary of the overall strategy for the validation of a facility. This Validation Master Plan provides an overview of the each process and describes the validation approach along with supporting validation rationale.

This VMP addresses the all activities related to equipment, utilities, processes, systems, and procedures that may impact the product quality.  Specific systems, equipment, utilities, and procedures to be qualified and processes to be validated shall be determined based on documented risk assessment.

The purpose of the validation plan is to demonstrate that the critical equipment, systems, and processes perform as designed and intended.  All validation will be conducted prospectively following written and approved protocols.  Change control and qualification of equipment and systems will be conducted in a manner consistent with a company's policies and procedures.  Specific equipment, systems, and processes to be validated will be determined based on a documented risk assessment.  

Download the example Validation Master Plan.

Download the accompanying presentation "Writing Effective Validation Protocols and Validation Master Plans," from IVT's 15th Annual Validation Week, Philadelphia, PA, October 2009.

This article was originally published for IVT - read article on IVT here: Example Validation Master Plan | IVT.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: IVT,
Click here